The GLP-1 story has outgrown its headlines. What began as a single class of blood-sugar compounds has splintered into a fast-moving family of research peptides, each engaging a different set of receptors and each behaving differently in the lab. For anyone trying to read the science rather than the marketing, the differences between these compounds have become the single most important thing to understand.
The peptides most often grouped under the “GLP-1” umbrella are not variations on one molecule. They are separated by which receptors they activate, and that distinction changes almost everything about how a compound behaves in a study.
One receptor, two, or three
Semaglutide is the benchmark of the class. It activates the GLP-1 receptor alone, and because it has been studied the longest, it serves as the reference point against which every newer compound is measured. When a peptide is described simply as “GLP-1,” semaglutide is usually the mental model behind the phrase.
Tirzepatide adds a second target. It is a dual agonist, engaging both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second pathway is why tirzepatide is treated as a distinct compound rather than a stronger version of the first. GIP signalling shapes the metabolic picture in ways GLP-1 activity alone does not.
Retatrutide goes further still, as a triple agonist engaging GLP-1, GIP, and the glucagon receptor. The addition of glucagon-receptor activity is what places retatrutide in a category of its own and explains the unusually intense research interest around it.
A fourth compound, cagrilintide, is frequently named alongside these three but works through an entirely separate mechanism. It is an amylin analogue, acting on a different metabolic pathway rather than the incretin receptors. For that reason, it is typically studied in combination rather than as a straight substitute.
The practical lesson for anyone designing or interpreting research is blunt: because the receptors engaged differ, the results are not interchangeable. A finding for a dual agonist cannot be assumed to carry over to a single or triple agonist. Sound comparative study design, and honest reading of the literature, depends on keeping these mechanisms straight. A clear, side-by-side breakdown of these compounds and their standards can be found in this overview of research-grade GLP-1 peptides in Canada.
The variable that rarely makes headlines: purity
Coverage of GLP-1 compounds fixates on outcomes. What gets far less attention is the quality of the material a study actually uses. In peptide research, that is not a footnote. It is a precondition.
A peptide is only useful for research if what’s in the vial is genuinely what the label claims, at the stated concentration and purity. A compound that is 90% pure, or that carries the wrong analogue, produces data that looks real and means nothing. This is why serious sourcing rests on two pillars: independent verification and documentation.
The benchmarks are worth knowing. Reputable suppliers test to a high purity threshold, commonly ≥99% by HPLC (high-performance liquid chromatography), with 98% often cited as the minimum acceptable floor, and back each production run with a batch-specific certificate of analysis rather than a generic one. Independent, third-party labs such as Janoshik are used precisely because outside testing carries more weight than in-house assurances alone. In a research setting, that paper trail is the difference between a result you can defend and one you can’t.
Handling is part of the data
Sourcing is only half the chain. These peptides ship lyophilized (freeze-dried) and require reconstitution with bacteriostatic water before use. Inconsistent preparation, whether from the wrong diluent, careless measurement, or poor storage, introduces silent variables that can undermine an otherwise well-designed study.
The water itself is part of that chain, and it is the step most people overlook. Bacteriostatic water is not a commodity where the source stops mattering. Research-grade work calls for pharmaceutical-grade bacteriostatic water from a known, regulated manufacturer, such as Pfizer’s Bacteriostatic Water for Injection, rather than unlabeled or generic product imported from overseas with no verifiable quality control. The same logic that governs the peptide governs what you dissolve it in: if you cannot trace where a material was made and to what standard, you cannot trust what it adds to your sample. Keeping both the compound and the diluent inside North American, regulated supply chains removes a variable that cheap imported water quietly introduces.
Cold-chain-appropriate shipping and correct storage after reconstitution belong to the same quality chain as purity testing. A 99% compound handled badly is no longer a 99% compound at the bench.
Reading the field responsibly
The GLP-1 space will keep expanding. New agonists and combinations are already moving through the pipeline, and the temptation to treat them as interchangeable will only grow as the list lengthens. The researchers who get the most from the literature hold two ideas at once: mechanism determines behaviour, and data is only ever as trustworthy as the material behind it.
None of the compounds discussed here are pharmaceuticals, and none are intended for human consumption. They are research-grade peptides for laboratory study only. But within that context, the fundamentals never change: know which receptor you are working with, verify what is in the vial, and document it. Those three habits are what separate results you can build on from numbers you cannot.